-

Ei.Ventures Announce Engagement With Tioga Research to Develop Transdermal Patch for Psilocin Delivery

MAUI, Hawaii & SAN DIEGO--(BUSINESS WIRE)--Noted psychedelic medicine start-up Ei.Ventures is excited to announce their engagement with Tioga Research to develop a transdermal patch for sustained delivery of psilocin, the active ingredient in psilocybin mushrooms, for mental health applications.

David Nikzad, the CEO of Ei.Ventures notes, “we are over the moon to join with one of the top transdermal delivery research specialists, Tioga Research, to begin developing products that could potentially help millions of people manage their mental health issues – depression, anxiety, PTSD, etc. with a patch. Additionally, with the increasing legality and popularity of psilocybin mushrooms, transdermal delivery could become a popular method for micro-dosing which helps with mental clarity and mood stabilization as well.”

John M. Newsam, CEO of Tioga Research adds, “By working with Ei.Ventures on a blue sky project of this nature, we will deploy our proprietary technologies and deep expertise to address key psilocin formulation issues, such as delivery and stability. A transdermal delivery route can circumvent issues with oral administration, such as nausea.”

EI.Ventures is focused on developing botanical active pharmaceutical ingredients for the psychedelic supply chain, novel psychedelic compounds for various indications, and unique delivery mechanisms and treatment protocols. In addition to their future regulated psychedelic line, Ei.Ventures will release their MANA range of functional mushroom nutraceuticals for improving well-being and health in Q3 2021.

Tioga Research supports the research and early development of skin-applied products, offering formulation innovation, skin permeation screening, and GLP IVRT/IVPT services. In addition, the company has pioneered high throughput experimentation (“HTE”) technologies for screening skin delivery. Tioga Research was founded in 2011 to support innovations in skin-applied products, especially topical and transdermal drug products, including skincare products and cosmetics. With headquarters and laboratory operations in San Diego, CA, and a business presence in the UK to support clients in Europe, Tioga Research has become a preferred service provider for an impressive portfolio of clients across the Americas, Europe, and Asia. Tioga Research has been a subsidiary of Encube Ethicals since early 2020, enabling clients to leverage the combined strengths of both organizations from early formulation innovation to commercial manufacturing.

For more information on Ei.Ventures, please go to https://invest.ei.ventures/. For media needs, please contact Susan von Seggern at susan@susanvonseggern.com or 213-840-0077.

Forward Looking Statements: Certain information set forth in this presentation, together with any supplements and any other information that may be furnished to prospective investors by the Company in connection therewith, contains “forward-looking statements” and “forward-looking information” within the meaning of applicable United States securities legislation (referred to herein as forward-looking statements). Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which include but are not limited to statements related to activities, events or developments that Ei.Ventures expects or anticipates will or may occur in the future, statements related to the Company’s business strategy objectives and goals, and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections ,assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as “may”, “will”, “could”, “would”, “anticipate”, ‘believe”, expect”, “intend”, “potential”, “estimate”, “budget”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions or the negatives thereof. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.

Contacts

Susan von Seggern
susan@susanvonseggern.com
213-840-0077

Ei.Ventures


Release Summary
Ei.Ventures announce engagement with Tioga Research to develop a transdermal patch for the active ingredient in psilocybin mushrooms, psilocin.
Release Versions

Contacts

Susan von Seggern
susan@susanvonseggern.com
213-840-0077

Social Media Profiles
More News From Ei.Ventures

Ei.Ventures and Orthogonal Thinker Acquire 12x12 Estate in The Sandbox in Anticipation of PSLY.COM Launch Post-Merger with Mycotopia Therapies in Q1 2022

MIAMI--(BUSINESS WIRE)--Ei.Ventures, along with Orthogonal Thinker, is excited to announce the acquisition of a 12x12 estate in The Sandbox, a virtual world where players can build, own, and monetize their gaming experiences on the Ethereum blockchain. This purchase represents the third-largest land sale in the Metaverse and is valued at $2.22M. The land will be called PSLY.COM, the name of the soon-to-be merged company of Ei.Ventures with Mycotopia Therapies. After only a week on the platform,...

Ei.Ventures Closes Out an Exciting 2021, Heads into 2022 Leading the Way in Psychedelic Medicine Development, Fundraising and more

MIAMI--(BUSINESS WIRE)--First and foremost the Ei.Ventures’ Reg A+ raise has been incredible. Support from investors from all over the country has topped expectations. As it stands, Ei.Ventures has raised $19,914,863 of a $50 million qualification. With new studies emerging showing that microdosing psychedelics has a clear association with fewer symptoms of depression, anxiety, and stress, it’s no wonder there is such a desire to see Ei.Ventures’ Psilly and other psychedelic medicines hit the m...

Ei.Ventures Partners With The3rdBevCo for PSILLI™, a line of Mushroom Infused Functional Sparkling Waters

RONKONKOMA, N.Y. & MIAMI--(BUSINESS WIRE)--Mushroom R&D company Ei.Ventures partners with functional beverage company The3rdBevCo on first line of mushroom-infused sparkling waters, PSILLI™....
Back to Newsroom